Immunocore Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Immunocore Holdings plc income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue310.20249.43174.3626.5230.11
Cost of Revenue2.731.041.09100.250.00
Gross Profit307.47248.39173.2726.5230.11
Operating Expenses
Research & Development222.15163.55101.9273.2374.81
Selling, General & Administrative155.78144.50123.0688.4045.74
Operating Expenses377.93308.94224.98161.63119.40
Operating Income-70.46-60.55-51.71-135.11-89.29
Other Income/Expense
Interest Income25.6217.993.760.070.71
Interest Expense18.84-5.155.415.573.11
Other Income/Expense10.75-14.0712.480.064.33
Income
Income Before Tax-52.94-60.89-40.88-140.93-87.36
Income Tax Expense-1.85-5.6011.66-9.41-13.27
Net Income-51.09-55.29-52.54-131.52-74.09
Net Income - Continuous Operations-51.09-55.29-52.54-180.030.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-29.89-51.65-30.14-166.72-75.28
EBIT-34.09-55.74-35.47-135.16-84.25
Depreciation & Amortization4.204.095.347.598.80
Earnings Per Share
Basic EPS-1.00-1.00-1.00-3.00-2.00
Diluted EPS-1.00-1.00-1.00-3.00-2.00
Basic Shares Outstanding49.9948.8945.8042.4931.78
Diluted Shares Outstanding49.9948.8945.8042.4931.78